NCT06674577View on ClinicalTrials.gov

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

476

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions
IgA Nephropathy (IgAN)Renal and Urinary DisordersBerger Disease
Interventions
DRUG

Atacicept 150 mg

"The atacicept drug product is available as a ready to use injection solution in the following prefilled syringe (PFS) that is composed of: \*BD Hypak™ SCF™ Barrel Glass barrel 1ml long with staked needle 27G ½ 5B with Rigid Needle Shield BD260 \*BD SCF™ Stopper 1ml long W4023 Flurotec"

Trial Locations (1)

94005

Vera Therapeutics, Brisbane

All Listed Sponsors
lead

Vera Therapeutics, Inc.

INDUSTRY